A Comparative Study of the Management of Stage 2 hypertension by Combined therapy with Losartan, Amlodipine and Hydrochlorothiazide

Reza  Jafarzadeh Esfehani; Azadeh  Mahmoodi Gharai; Ali  Jafarzadeh Esfehani; Afsaneh  Rezaie Kalat; Faezeh  Abbasi; Majid  Jalalyazdi

International Cardiovascular Research Journal

The Official Annually Journal of Cardiovascular Research Center, Shiraz University of Medical Sciences

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Boards & Committees Indexing and Listing Sources Journal Metrics Publication Ethics and Publication Malpractice Statement Contact Us Support Reviewer and AE Registration Form

APC

Authors Guide Submit Manuscript

A Comparative Study of the Management of Stage 2 hypertension by Combined therapy with Losartan, Amlodipine and Hydrochlorothiazide

Author(s):

Reza Jafarzadeh Esfehani¹,

Azadeh Mahmoodi Gharai²,

Ali Jafarzadeh Esfehani³,

Afsaneh Rezaie Kalat⁴,

Faezeh Abbasi¹,

Majid Jalalyazdi^5,*

11Education Development Center, Sabzevar University of Medical Sciences, Sabzevar, Iran

2Mashhad University of medical science, Mashhad, Iran

32Mashhad University of medical science, Mashhad, Iran

4Education Development Center, Sabzevar University of Medical Sciences, Sabzevar, Iran

5Cardiology Department, Sabzevar University of Medical Sciences, Sabzevar, Iran

International Cardiovascular Research Journal:Vol. 6, issue 3; e12801

Published online:Oct 20, 2011

Article type:Research Article

Received:May 09, 2017

Accepted:Oct 20, 2011

How to Cite:Reza Jafarzadeh EsfehaniAzadeh Mahmoodi GharaiAli Jafarzadeh EsfehaniAfsaneh Rezaie KalatFaezeh AbbasiMajid Jalalyazdiet al.A Comparative Study of the Management of Stage 2 hypertension by Combined therapy with Losartan, Amlodipine and Hydrochlorothiazide.Int Cardiovasc Res J.6(3):e12801.

Abstract

Background: The most effective and accurate treatment of hypertensive patients reduces cardiovascular events and improves the quality of life.
Objective: This study compared the efficacy and safety of combined (combination therapy) with an angiotensin-receptor blocker (ARB) a calcium-channel blocker (CCB) (Losartan / Amloidipine 50/10mg) vs maximal combination doses of ARB with hydrochlorothiazide (Losartan /HCTZ 100/25 mg) and maximal combination doses of CCB with HCTZ (Amlodipine /HCTZ 10/25 mg) in the management of stage 2 hypertension.
Methods: This randomized clinical trial (RTC) comprised 478 hypertensive patients with mean age 50.5±5.21 years, and took place between January 2010 and December 2011 in Vasei Hospital clinic in Sabzevar. Antihypertensive drugs were washed out after 5 days of discontinuation of drugs and the patients with mean blood pressure in sitting position ≥ 160 and <200 mmHg in systole and ≥ 100 and <110 mmHg in diastole were randomized into three groups: Losartan / Amlodipine 50/10 mg (n =164) , Losartan / HCTZ 100/25 mg (n =155) and Amlodipine / HCTZ 10/25 mg (n =159). The end point was reaching the blood pressure below 140/90 within 56 days of treatment in each group.
Results: There was a significant difference in systolic blood pressure reductions between treatment groups (P<0.001) and also there was a significant difference between groups in reducing diastolic blood pressure (P<0.01). The highest systolic and diastolic blood pressure reduction respectively was found in Amlodipine/losartane and losartane/HTCZ group. The ANCOVA analysis revealed that only treatment regimen had a significant effect (P=0.01) and other factor including Age, Gender, Diabetes Mellitus, Smoking and High serum cholesterol didn’t have significant effect on blood pressure reduction.
Conclusion: ARB/CCB combination therapy reduced blood pressure more effectively than the maximal doses of ARB or CCB with HCTZ in stage 2 hypertensive patients within this period of study.

Keywords

Angiotensin Receptor Blocker

Calcium Channel Blocker

Hypertension

Fulltext

References

1.
The references are available in PDF.

comments